nach oben

Erschienen in:

30.03.2016 | Main topic

Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic

verfasst von: R. J. King, Prof. P. J. Grant

Erschienen in: Herz | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Diabetes is associated with the development of premature cardiovascular disease (CVD), which relates to the clustering of risk factors such as dyslipidaemia, hypertension, obesity and hyperglycaemia in the presence of insulin resistance. In addition, diabetes is associated with an inflammatory and pro-thrombotic environment, exacerbating the development of atherothrombosis. Insulin resistance and hyperglycaemia both contribute to the development of endothelial cell dysfunction and increased oxidative stress, culminating in accelerated atherosclerosis. Clot formation and function are also directly affected by insulin resistance and hyperglycaemia, with increased levels of coagulation factors and anti-fibrinolytic proteins and a fibrin network that is more resistant to lysis, coupled with increased platelet activation.

It is well recognised that the intensification of glycaemic control leads to a reduction in microvascular complications in type 1 and type 2 diabetes; however, the same is less clear with macrovascular disease. Several randomised studies have attempted to address the effect of short-, medium- and long-term glycaemic control on cardiovascular outcomes, with mixed results. The overall interpretation of these trials suggests that intensive glycaemic control in patients with a relatively short duration of diabetes, without very poor control and with no CVD, might be safe and associated with fewer cardiovascular events.

This review will summarise the effects of hyperglycaemia on the development of atherothrombosis and examine key cardiovascular outcome trials following intensive glucose control.

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed

Cubbon RM, Wheatcroft SB, Grant PJ et al (2007) Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 28:540–545CrossRefPubMed

Kahn MB, Cubbon RM, Mercer B et al (2012) Association of diabetes with increased all-cause mortality following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in the contemporary era. Diabetes Vasc Dis Res 9:3–9CrossRef

Anonymous (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986CrossRef

Anonymous (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef

Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S (2011) Genetic syndromes of severe insulin resistance. Endocr Rev 32:498–514CrossRefPubMed

Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601–2610CrossRefPubMedPubMedCentral

Perticone F, Ceravolo R, Candigliota M et al (2001) Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50:159–165CrossRefPubMed

Kohler HP, Grant PJ (2000) Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease. N Engl J Med 342:1792–1801CrossRefPubMed

10.

Festa A, D’Agostino R Jr., Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131–1137CrossRefPubMed

11.

Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie, Szklo M (1991) Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 91:191–205CrossRefPubMed

12.

Heywood DM, Mansfield MW, Grant PJ (1996) Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 75:401–406PubMed

13.

Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54:570–575CrossRefPubMed

14.

Thorand B, Lowel H, Schneider A et al (2003) C‑reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICa Augsburg cohort study, 1984–1998. Arch Intern Med 163:93–99CrossRefPubMed

15.

Balletshofer BM, Rittig K, Enderle MD et al (2000) Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780–1784CrossRefPubMed

16.

Mansfield MW, Heywood DM, Grant PJ (1996) Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 94:2171–2176CrossRefPubMed

17.

Mansfield MW, Stickland MH, Grant PJ (1997) PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost 77:357–361PubMed

18.

Naseem KM (2005) The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 26:33–65CrossRefPubMed

19.

Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF (2000) Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 101:1982–1989CrossRefPubMed

20.

Bohl KS, West JL (2000) Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials 21:2273–2278CrossRefPubMed

21.

Clapp BR, Hingorani AD, Kharbanda RK et al (2004) Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 64:172–178CrossRefPubMed

22.

Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon ROIII (1995) Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 92:320–326CrossRefPubMed

23.

Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA (2003) Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 89:993–997CrossRefPubMedPubMedCentral

24.

Levi M, van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38:S26–S34CrossRefPubMed

25.

Cirillo P, Golino P, Calabro P et al (2005) C‑reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 68:47–55CrossRefPubMed

26.

Singh U, Jialal I (2006) Oxidative stress and atherosclerosis. Pathophysiology 13:129–142CrossRefPubMed

27.

Taylor AA (2001) Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 30:983–997CrossRefPubMed

28.

Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed

29.

Robertson RP, Harmon JS (2006) Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41:177–184CrossRefPubMed

30.

Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121:2111–2117CrossRefPubMedPubMedCentral

31.

Goossens GH (2008) The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 94:206–218CrossRefPubMed

32.

Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C‑reactive protein on human endothelial cells. Circulation 102:2165–2168CrossRefPubMed

33.

Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880CrossRefPubMed

34.

Torimoto K, Okada Y, Mori H, Tanaka Y (2013) Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol 12:1CrossRefPubMedPubMedCentral

35.

Okada K, Hibi K, Gohbara M et al (2015) Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. Cardiovasc Diabetol 14:111CrossRefPubMedPubMedCentral

36.

Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687CrossRefPubMed

37.

Gerrits AJ, Koekman CA, van Haeften TW, Akkerman JW (2010) Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes 59:1487–1495CrossRefPubMedPubMedCentral

38.

Grant PJ (2007) Diabetes mellitus as a prothrombotic condition. J Intern Med 262:157–172CrossRefPubMed

39.

Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS (1997) Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 46(Suppl 2):9–13CrossRef

40.

Undas A, Wiek I, Stepien E, Zmudka K, Tracz W (2008) Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 31:1590–1595CrossRefPubMedPubMedCentral

41.

Dunn EJ, Ariens RA (2004) Fibrinogen and fibrin clot structure in diabetes. Herz 29:470–479CrossRefPubMed

42.

Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:240–259CrossRefPubMed

43.

Pieters M, van Zyl DG, Rheeder P et al (2007) Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thromb Res 120:439–446CrossRefPubMed

44.

Hess K, Alzahrani SH, Mathai M et al (2011) A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 55(4):1103–1113CrossRefPubMed

45.

Dunn EJ, Ariens RA, Grant PJ (2005) The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48:1198–1206CrossRefPubMed

46.

Dunn EJ, Philippou H, Ariens RA, Grant PJ (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071–1080CrossRefPubMed

47.

Jorneskog G, Egberg N, Fagrell B et al (1996) Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39:1519–1523CrossRefPubMed

48.

Pieters M, Covic N, van der Westhuizen FH et al (2008) Glycaemic control improves fibrin network characteristics in type 2 diabetes – a purified fibrinogen model. Thromb Haemost 99:691–700PubMedPubMedCentral

49.

Seljeflot I, Larsen JR, Dahlgren S, Hanssen KF, Arnesen H (2006) Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients. J Thromb Haemost 4:686–688CrossRefPubMed

50.

Ajjan RA, Gamlen T, Standeven KF et al (2013) Diabetes is associated with post-translational modifications in plasminogen resulting in reduced plasmin generation and enzyme specific activity. Blood 122(1):134–142CrossRefPubMed

51.

Agren A, Jorneskog G, Elgue G, Henriksson P, Wallen H, Wiman B (2014) Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care 37:2007–2014CrossRefPubMed

52.

Howes JM, Richardson VR, Smith KA et al (2012) Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diabetes Vasc Dis Res 9:216–225CrossRef

53.

Ferreira IA, Mocking AI, Feijge MA et al (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26:417–422CrossRefPubMed

54.

Hess K, Grant PJ (2011) Inflammation and thrombosis in diabetes. Thromb Haemost 105(Suppl 1):43–54CrossRef

55.

Watala C (2005) Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 11:2331–2365CrossRefPubMed

56.

Angiolillo DJ, Suryadevara S (2009) Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 23:375–388CrossRefPubMed

57.

Trovati M, Anfossi G (1998) Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia 41:609–622CrossRefPubMed

58.

Ferroni P, Basili S, Falco A, Davi G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2:1282–1291CrossRefPubMed

59.

Kannel WB, Neaton JD, Wentworth D et al (1986) Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. multiple risk factor intervention trial. Am Heart J 112:825–836CrossRefPubMed

60.

Jerums G, Panagiotopoulos S, Ekinci E, MacIsaac RJ (2015) Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. J Hum Hypertens 29:473–477CrossRefPubMed

61.

Anonymous (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high–risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRef

62.

Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696CrossRefPubMed

63.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393CrossRefPubMed

64.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591CrossRefPubMed

65.

Li G, Zhang P, Wang J et al (2014) Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2:474–480CrossRefPubMed

66.

Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154CrossRefPubMed

67.

Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298CrossRefPubMed

68.

Green JB, Bethel MA, Armstrong PW et al (2015) Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373:232–242CrossRefPubMed

69.

White WB, Bakris GL, Bergenstal RM et al (2011) EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 162:620–626CrossRefPubMed

70.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373:2117–2212CrossRefPubMed

71.

Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefPubMed

72.

Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMed

73.

Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828CrossRefPubMed

74.

Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed

75.

Anonymous (2005) Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 353:2643–2653CrossRef

76.

Anonymous (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854–865CrossRef

77.

Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565–1576CrossRefPubMed

Titel: Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic
verfasst von: R. J. King
Prof. P. J. Grant
Publikationsdatum: 30.03.2016
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 3/2016
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-016-4414-8

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Novel insight into the dangerous connection between diabetes and heart failure

Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes

Relationship between neutrophil–lymphocyte ratio and in-hospital mortality

Efficacy and safety of zero-fluoroscopy ablation for supraventricular tachycardias